SEC Form 4 · accession 0000899243-18-009445

Q32 Bio Inc. · QTTB

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Director · 10% Owner

Period of report

Apr 2, 2018

Accepted (ET)

Apr 4, 2018 · 4:24 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001661998

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock^F1,F2,F3	Apr 2, 2018	C	5,392,037	$0.00	A	6,722,076	I	See footnote

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Series A Preferred Stock^F2,F3,F4	—	Apr 2, 2018	C	4,204,502	D	—	—	Common Stock	4,204,502	0	I
Series B Preferred Stock^F2,F3,F4	—	Apr 2, 2018	C	1,187,535	D	—	—	Common Stock	1,187,535	0	I

F1Following the transactions reported herein, includes 1,276,838 shares of common stock held of record by 5AM Ventures IV, L.P. ("Ventures IV") and 53,201 shares of common stock held of record by 5AM Co-Investors IV, L.P. ("Co-Investors IV").
F25AM Partners IV, LLC ("Partners IV") is the sole general partner of Ventures IV and Co-Investors IV. Dr. John Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage, are the managing members of Partners IV, and have shared voting and investment power over the shares beneficially owned by Ventures IV and Co-Investors IV. Each of Partners IV, Dr. Diekman, Mr. Schwab and Dr. Rocklage disclaim beneficial ownership of such shares except to the extent of its or their recurring interest therein.
F3The Reporting Person is an affiliate of Partners IV and disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein.
F4Upon closing of the Issuer's initial public offering, each share of preferred stock was automatically converted into one share of the Issuer's common stock.